CA3265409A1 - Méthodes et compositions pour le traitement de l'apnée du sommeil - Google Patents

Méthodes et compositions pour le traitement de l'apnée du sommeil

Info

Publication number
CA3265409A1
CA3265409A1 CA3265409A CA3265409A CA3265409A1 CA 3265409 A1 CA3265409 A1 CA 3265409A1 CA 3265409 A CA3265409 A CA 3265409A CA 3265409 A CA3265409 A CA 3265409A CA 3265409 A1 CA3265409 A1 CA 3265409A1
Authority
CA
Canada
Prior art keywords
compositions
methods
sleep apnea
treating sleep
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3265409A
Other languages
English (en)
Inventor
Lawrence G. Miller
Luigi Taranto-Montemurro
Ronald FARKAS
Yoshitaka Ichikawa
Original Assignee
Apnimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc filed Critical Apnimed Inc
Publication of CA3265409A1 publication Critical patent/CA3265409A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3265409A 2022-09-02 2023-08-30 Méthodes et compositions pour le traitement de l'apnée du sommeil Pending CA3265409A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263403469P 2022-09-02 2022-09-02
US63/403,469 2022-09-02
PCT/US2023/031509 WO2024049885A1 (fr) 2022-09-02 2023-08-30 Méthodes et compositions pour le traitement de l'apnée du sommeil

Publications (1)

Publication Number Publication Date
CA3265409A1 true CA3265409A1 (fr) 2024-03-07

Family

ID=88188874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3265409A Pending CA3265409A1 (fr) 2022-09-02 2023-08-30 Méthodes et compositions pour le traitement de l'apnée du sommeil

Country Status (7)

Country Link
EP (1) EP4580630A1 (fr)
JP (1) JP2025527796A (fr)
KR (1) KR20250057804A (fr)
CN (1) CN119789855A (fr)
AU (1) AU2023335927A1 (fr)
CA (1) CA3265409A1 (fr)
WO (1) WO2024049885A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
MY176401A (en) 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
US11339135B2 (en) 2016-11-30 2022-05-24 Mitsubishi Tanabe Pharma Corporation Method for producing triazine compound
CA3117766A1 (fr) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methodes et compositions pour le traitement de l'apnee du sommeil
BR112021015600A2 (pt) * 2019-02-08 2021-10-05 The Brigham And Women's Hospital, Inc. Métodos e composições para tratamento da apneia do sono
US20240009201A1 (en) 2020-10-26 2024-01-11 Mineralys Therapeutics, Inc. Cyp11b2 beta hydroxylase inhibitors for hypertension
WO2022204228A1 (fr) * 2021-03-24 2022-09-29 Apnimed, Inc. (Delaware) Méthodes et compositions pour traiter l'apnée du sommeil

Also Published As

Publication number Publication date
WO2024049885A1 (fr) 2024-03-07
CN119789855A (zh) 2025-04-08
KR20250057804A (ko) 2025-04-29
JP2025527796A (ja) 2025-08-22
EP4580630A1 (fr) 2025-07-09
AU2023335927A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
IL276247A (en) Methods and materials for the treatment of sleep apnea
IL285197A (en) Methods and preparations for the treatment of sleep apnea
AU2022298632A9 (en) Methods for treating obstructive sleep apnea
EP4096675A4 (fr) Compositions et procédés de traitement de la covid longue
EP4341382A4 (fr) Composés et méthodes de traitement de maladies
EP4175978A4 (fr) Compositions et méthodes pour traiter des maladies médiées par crp
IL307186A (en) Methods and preparations for treating sleep apnea
EP3989985A4 (fr) Procédés et compositions pour le traitement du cancer du pancréas
HK40112418A (en) Methods and compositions for treating sleep apnea
HK40108218A (en) Methods and compositions for treating sleep apnea
HK40041686A (en) Compositions and methods for treating obstructive sleep apnea
HK40059516A (en) Methods and compositions for treating sleep apnea
AU2021901369A0 (en) Compositions for treating inflammatory airway disease and uses thereof
AU2023416981A1 (en) Method of treating sleep disruptions and composition for use therein
EP4440547A4 (fr) Compositions et procédés pour le traitement de l'alopécie
AU2022901200A0 (en) Compositions and methods for treating disease
AU2022900261A0 (en) Compositions and methods for treating disease
CA3274729A1 (fr) Compositions et procédés de modulation du sommeil et leurs utilisations
CA3281552A1 (fr) Compositions et méthodes de traitement de l'hyperprocalcitonémie
CA3278586A1 (fr) Compositions et méthodes de traitement d'alpha-synucléinopathies
HK40116997A (en) Compositions and methods for treating disease
AU2023903544A0 (en) Methods and compositions for treating skin
HK40131895A (en) Compositions and methods for treating pulmonary conditions
CA3281039A1 (fr) Compositions et méthodes de traitement d'affections pulmonaires
AU2021903624A0 (en) Compositions and methods for treating disease

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250219

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250517

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250517

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250517

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250521

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704